NCT03276156

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD)and safety of Apatinib combined with S-1 as Second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Conditions

• Gastric Cancer

Interventions

Type	Name	Description
DRUG	Apatinib plus S-1	Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);

Timeline

• Start date: 2016-02-23
• Primary completion: 2018-02-22
• Completion: 2018-02-22
• First posted: 2017-09-08
• Last updated: 2017-09-08

Locations

1 site across 1 country: China